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Abstract.   Staphylococcus aureus has proven to be a major pathogen with the emergence of 1 
methicillin-resistant S. aureus (MRSA) infections and recently with heteroresistant vancomycin 2 
intermediate S. aureus (hVISA) and vancomycin intermediate S. aureus (VISA) infections.  While 3 
vancomycin is traditionally a first line and relatively effective antibiotic, its continued use is under 4 
question, as reports of heteroresistance in S. aureus isolates are increasing.  Both hVISA and VISA 5 
infections are associated with complicated clinical courses and treatment failures.  The prevalence, 6 
mechanism of resistance, clinical significance, and laboratory detection of hVISA and VISA 7 
infections are not conclusive, making it difficult to apply research findings to clinical situations.  8 
We provide an evidence based review of S. aureus isolates expressing heterogenic and reduced 9 
susceptibility to vancomycin.  10 
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Introduction 11 
Methicillin-resistant Staphylococcus aureus (MRSA) is the most commonly encountered bacteria 12 
in hospitals and community settings1 and is associated with invasive infections ranging in severity 13 
from mild to fatal.2 Vancomycin is considered the standard treatment for empiric and definitive 14 
serious MRSA infections.2  In recent years, infections caused by MRSA with reduced 15 
susceptibility to vancomycin have emerged.  The formation of intermediate resistant isolates is 16 
likely caused by selection pressure from ever-present and longstanding use of vancomycin.3-5  Poor 17 
patient outcomes are attributed to heteroresistant vancomycin intermediate S. aureus (hVISA) and 18 
vancomycin intermediate S. aureus (VISA) infections.6-8  Herein we review the prevalence, 19 
laboratory detection and interpretation, resistance mechanisms, risk factors and outcomes, 20 
treatment options, and infection control strategies for hVISA and VISA.  Peer-reviewed 21 
publications were identified using PubMed, Embase, and Cochrane Central Register of Controlled 22 
Trials. 23 
 24 
Prevalence of hVISA and VISA 25 
The first clinical strain of S. aureus with intermediate resistance to vancomycin, designated Mu50, 26 
was reported in 1997 from Japan.9,10  The first hVISA isolate, designated Mu3, was identified in 27 
Japan one year earlier from a patient with MRSA pneumonia unresponsive to vancomycin.9  Since 28 
then, hVISA and VISA cases have been reported in the United States, United Kingdom, China, 29 
Australia, Turkey, France, Belgium, Germany, Italy, Brazil, and South Korea.11  The true 30 
prevalence of hVISA is unknown, and estimates vary widely because of non-standardized 31 
detection methodologies or absence of routine hVISA screening, variation in interpretation, 32 
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geographical location, clinical setting, and differing patient populations.12-19  Reported rates of 33 
hVISA throughout the world range from 0 to 73.7%.18   34 
 35 
One retrospective study evaluated MRSA strains with heterogenic intermediate resistance to 36 
vancomycin over a 22-year period in three Detroit hospitals.  The prevalence of these organisms 37 
increased from 2.2% (1986 – 1993) and 7.6% (1992 – 2002) to 8.3% between 2003 and 2007.16  38 
Only 14 of the 1,498 (0.93%) MRSA isolates were identified as VISA.  There was no apparent 39 
pattern of increasing prevalence over the three time periods for VISA isolates. An increase in 40 
hVISA was also described in  a similar retrospective study  from Turkey  of 1.6% in 1998 to 36% 41 
in 2001.20  Because clonality was not evaluated in either study, the increase in prevalence may 42 
have reflected clonal spread rather than true prevalence.  Prevalence may have been 43 
underestimated because the isolates were stored for prolonged periods in glycopeptide-free media, 44 
which may result in a loss of resistance.21  Two surveillance studies conducted in 2009 and 2011 45 
in over 40 U.S. medical centers determined rates of antimicrobial resistance among S. aureus 46 
isolates collected from patients with infections.22,23  The rates of hVISA among MRSA isolates in 47 
2011 were higher than in 2009 (1.2% vs. 0.4%, P = 0.003).22  Of note, strains of VISA were not 48 
detected.22,23 While the current prevalence of VISA is low, these organisms may become more 49 
common in the future.  Data suggests that heteroresistance is a precursor to VISA, therefore the 50 
suspected increase in prevalence of hVISA may predict more VISA infections.  Increased use of 51 
vancomycin provides selection pressure for further emergence of VISA.  Based on available data, 52 
hVISA appears to be on the rise, yet VISA still remains a rare occurrence.  Additional studies are 53 
needed to determine appropriate surveillance methods because retrospective studies are 54 
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complicated by the ability of hVISA to revert back to vancomycin-susceptible S. aureus (VSSA) 55 
and VISA to revert back to hVISA. 56 
 57 
hVISA and VISA Laboratory Detection and Interpretation 58 
Further discussion of hVISA and VISA require that clinical and microbiologic definitions are 59 
addressed.  In 2006, the Clinical and Laboratory Standards Institute (CLSI) lowered vancomycin 60 
minimum inhibitory concentration (MIC) breakpoints for S. aureus.24  The CLSI breakpoints by 61 
broth microdilution (BMD) currently define vancomycin susceptibility as an MIC  2 μg/mL, 62 
vancomycin-intermediate susceptibility as an MIC of 4 to 8 μg/mL, and vancomycin resistance as 63 
an MIC of 16 μg/mL (Table 1).25  Vancomycin MIC breakpoints were lowered in an effort to 64 
increase detection of potentially heterogeneous-intermediate isolates because of reported 65 
associations between vancomycin treatment failure and S. aureus isolates with MICs ≥ 4 66 
µg/mL.7,8,25  Heteroresistance refers to the presence of less susceptible subsets within a larger 67 
population of fully antimicrobial-susceptible microorganisms.5  When tested using routine 68 
methods, hVISA isolates are susceptible to vancomycin (MIC 2 μg/mL) but contain 69 
subpopulations that express reduced vancomycin susceptibility (MIC  4 μg/mL).11 70 
 71 
Detection of hVISA is a great challenge in clinical microbiology laboratories because reliable and 72 
practical methods are not currently available for routine use.    Heteroresistant subpopulations are 73 
present in low frequencies (1 x 106) and can grow in higher vancomycin concentrations than the 74 
MIC predicts.  Such small populations may not be detected by the inocula (5 x 105 CFU/mL)  75 
used in standard CLSI microbiology methods.   As a result, hVISA isolates are likely undetected 76 
in clinical laboratories that use traditional MIC testing methodology.13 Population analysis 77 
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profiling with area under the curve (PAP-AUC) is the current reference standard method for 78 
confirming hVISA and is the most reliable and reproducible test. However PAP-AUC is labor-79 
intensive, time consuming (3 to 5 days), and costly for use in clinical microbiology 80 
laboratories.17,19,26  Consequently, several screening methods have been developed, such as 81 
glycopeptide resistance detection (GRD), marcromethod E-test (MET) and brain heart infusion 82 
(BHI) screen agar plates (Table 2).27-29  However, none of these tests have the same degree of 83 
sensitivity and specificity as the PAP-AUC test, with issues of reproducibility and variability, in 84 
reporting results.19 Until a suitable hVISA detection method becomes available for use in clinical 85 
microbiology laboratories, routine testing is not currently recommended.2  Currently, clinical 86 
screening for hVISA isolates in high-risk patients is favored (Table 3), particularly in patients who 87 
do not respond to vancomycin.   Further research is warranted to develop a detection method that 88 
is practical, cost-effective, and reliable for routine use in clinical settings.   89 
 90 
Non-automated MIC methods for the detection of VISA are recommended by the Centers for 91 
Disease Prevention and Control (CDC).30  Acceptable non-automated MIC methods for detecting 92 
VISA include BMD per CLSI, agar dilution, and Etest (0.5 McFarland). 30  Though automated 93 
methods and vancomycin screen agar plates can be useful in the detection of VISA isolates with a 94 
vancomycin MIC of 8 μg/mL, sensitivity levels have not been determined for S. aureus with 95 
vancomycin MICs of 4 μg/mL.30  In these situations, a second method, such as BMD per CLSI 96 
criteria, should be used to confirm VISA isolates.30  97 
 98 
Current susceptibility testing methods do not consistently distinguish between MICs of 1 and 2 99 
μg/mL.2,31 Therefore, laboratory results should indicate the methodology used, because 100 
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vancomycin MIC results will differ between methods and may alter treatment decisions.11  In 101 
comparison to the CLSI BMD method, automated detection methods, particularly Phoenix system 102 
and Vitek, tend to underestimate the MIC, while E-test and MicroScan (prompt method) may 103 
overestimate the MIC.31  Precision of these methods is clinically important as higher vancomycin 104 
MICs (> 1.5 μg/mL) are associated with poorer outcomes (e.g., increased mortality, recurrence, 105 
delayed response, treatment failure, prolonged hospitalization), particularly in high inoculum 106 
infections and with a higher proportion of hVISA presence.25,32  Alternative therapies should be 107 
considered for patients receiving vancomycin therapy who are persistently bacteremic (≥ 7 days) 108 
or who have no clinical improvement despite source control with an MIC of  1.5 μg/mL by 109 
Etest.2,31,32 110 
 111 
Resistance Mechanisms of hVISA and VISA 112 
Evidence suggests that hVISA and VISA arise during continued or sub-optimal exposure to 113 
vancomycin.7,33  The proposed mechanism is selective pressure by vancomycin resulting in the 114 
development of rare vancomycin-resistant clones that progress to hVISA and, with continued-115 
exposure, to a uniform population of VISA clones.5,9  These isolates have significant differences 116 
in cell physiology, including morphologic changes and genetic alterations.  Strains of hVISA and 117 
VISA are characterized by thicker cell walls that correlate with increased vancomycin MICs.34  118 
Cell wall thickening impairs intracellular penetration of vancomycin rendering it ineffective.5,34  119 
In addition, hVISA and VISA are associated with slower growth rates than fully susceptible 120 
strains, which may contribute to persistent and recurrent infections.35  Other mechanisms of 121 
resistance include alterations in transcriptional and metabolic genes and loss-of-function mutations 122 
that disturb critical cell wall biosynthesis.11  The accessory gene regulator (agr) operon directs 123 
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many critical virulence pathways, particularly the production of exotoxins.11  In hVISA and VISA 124 
strains, agr function is reduced, favoring the development of vancomycin resistance and 125 
potentially promoting biofilm production that ultimately enhances the survival of hVISA and 126 
VISA.33,36,37   127 
 128 
Risk Factors and Outcomes Associated with hVISA and VISA 129 
Heteroresistance has been reported in MRSA isolates with MICs as low as 0.5 µg/mL and in cases 130 
where vancomycin was minimally effective.6,16  Several studies have noted an increase in 131 
vancomycin treatment failures and mortality with vancomycin susceptible MRSA strains, 132 
particularly those with MICs of 1.5 or 2 µg/mL.25,32,38-40    A recent meta-analysis of 20 studies 133 
evaluated high versus low vancomycin MICs (≥ 1.5 µg/mL vs < 1.5 µg/mL, respectively) on 134 
clinical outcomes in adults with MRSA infections.40  An increased risk of failure was observed in 135 
the high MIC group compared to the low MIC group (relative risk [RR], 1.40; 95% confidence 136 
interval [CI], 1.15 – 1.71).   There was also a greater risk of overall mortality (RR, 1.45; 95% 137 
CI,1.08-1.87) in the high MIC group.  Although the investigators attempted to exclude hVISA 138 
isolates, hVISA presence was not tested in every study, which may have contributed to 139 
vancomycin treatment responses.  While most of the isolates were from blood, clinical 140 
heterogeneity cannot be excluded.  Another study evaluated 559 MRSA isolates and found an 141 
increased incidence of hVISA when the vancomycin MIC shifted from 1 to 2 μg/mL.41  The 142 
incidence of hVISA was nearly 40% in isolates with an MIC of 2 μg/mL, supporting the results of 143 
other studies that suggest the proportion of hVISA isolates are directly related to increases in 144 
vancomycin MIC.6,15,23,41   Increases in vancomycin MICs are hospital specific and perhaps caused 145 
by clonal outbreaks.  However, this highlights the trends of vancomycin tolerance, which may be 146 
9 
 
caused by overuse of vancomycin, sub-therapeutic vancomycin concentrations, high bacterial load, 147 
or slow vancomycin bactericidal activity.3,42   148 
 149 
Both hVISA and VISA have been identified in hospital and community strains of MRSA and in 150 
MSSA.16  The findings of studies that evaluated clinical predictors and outcomes of hVISA 151 
infections are inconsistent.  This may be attributed to the considerable heterogeneity of these 152 
studies, including differences in study design, clinical definitions, selection of isolates (initial 153 
isolate, final isolate, or random selection), patient populations, and testing methodologies.  154 
Commonly reported associations with hVISA infections include vancomycin treatment failure and 155 
high-inoculum MRSA infections (e.g., bacteremia, infective endocarditis, osteomyelitis, deep 156 
abscesses, and prosthetic device infections).6,7,14,33,43,44  Other potential predictors of  hVISA and 157 
VISA infections are prior MRSA infection or colonization (previous 3 months), previous 158 
vancomycin exposure (prior 6 months), initial low serum vancomycin trough levels (< 10 µg/mL), 159 
persistent bacteremia (≥ 7 days), and presence of indwelling devices (Table 2).7,8,12,14,44,45 46 160 
 161 
Patients with hVISA infections tend to experience prolonged clinical courses, suboptimal response 162 
to vancomycin therapy, and prolonged hospital stays.6-8,14,33,42,44 One retrospective case-control 163 
study compared the clinical features and outcomes of hVISA bacteremia (n = 27) and MRSA 164 
bacteremia (n = 223).14  Compared with MRSA bacteremia, patients with hVISA infections had 165 
significantly more days of bacteremia (median duration, 12 days vs. 2 days, respectively; P = 166 
0.005) and significantly higher rates of endocarditis (18.5% vs. 3.6%, respectively; P = 0.007) and 167 
osteomyelitis (25.9% vs. 7.2%, respectively; P = 0.006).14  Of note, patients in the hVISA group 168 
had significantly more prosthetic/implant devices (e.g., artificial heart valves, pacemakers, or 169 
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orthopedic implants) and surgical site infections (in the previous month) at baseline, which may 170 
have attributed to poorer outcomes.  In a small case series, glycopeptide treatment failure, (defined 171 
as a positive S. aureus blood culture after  7 days of glycopeptide therapy or a sterile site culture 172 
positive for S. aureus after  21 days of glycopeptide therapy) occurred in 19 of 25 (76%) patients 173 
with hVISA infections (bacteremia, endocarditis, osteomyelitis, or septic arthritis).8   174 
 175 
A retrospective, multicenter, matched cohort study compared the outcomes of hVISA versus 176 
vancomycin susceptible-MRSA (VS-MRSA) bloodstream infections (BSI) and found similar 177 
results.6  Study investigators concluded that rates of vancomycin treatment failure were 11 times 178 
higher for a patient with hVISA BSI (50/61, 82%) than VS-MRSA BSI (20/61, 32.8%; P <0.001).  179 
Patients with hVISA BSI were also more likely than patients with VS-MRSA BSI to have 180 
persistent bacteremia (59% vs. 21.3%, respectively; P <0.001), infection recurrence at 60 days 181 
(25.5% vs. 1.9%, respectively; P < 0.001), and longer hospital length of stay (median in days, 24 182 
vs. 16, respectively; P = 0.022).  While differences in 30-day MRSA infection-related mortality 183 
and all-cause 30-day mortality were not observed between  the hVISA BSI group and VS-MRSA 184 
BSI group (21.3% vs. 9.8%; P = 0.081 and 24.6% vs. 11.5%; P = 0.076, respectively).  Similarly, 185 
no other studies have been powered to detect a significant difference in mortality between hVISA 186 
and non-hVISA infections.  A recent systematic review and meta-analysis evaluated 30-day 187 
mortality from eight comparative hVISA studies.18  After combining the data, 30-day mortality 188 
between hVISA and VSSA infections were similar (OR, 1.18; 95% CI, 0.81-1.74).18  However, 189 
these findings may be limited by the variability in definitions used and the predominately 190 
retrospective designs of the original studies.  While the lack of association between hVISA and 191 
mortality can be partly explained by strain characteristics (e.g., decreased virulence) and host 192 
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immune responses, sufficiently sized studies are needed to accurately determine if such an 193 
association exits.47   194 
 195 
Infections caused by VISA may also lead to recurrent infections, prolonged fevers and bacteremia, 196 
vancomycin treatment failure, and increased hospital stay.7,12,33,44 In a single–center, retrospective 197 
study, 6 patients with VISA had a significantly longer duration of bacteremia compared to 22 with 198 
hVISA (12.1 ± 13.1 days vs. 3.3 ± 3.9 days, respectively; P = 0.001).43  Significant differences in 199 
mortality between VISA and hVISA were not observed. However, rates of attributable mortality 200 
between hVISA and VSSA (n = 215) were similar (9.1% vs. 8.4%, respectively) while those 201 
between VISA and VSSA (33.3% vs. 8.4%) were not.43  Although this study had several 202 
limitations including a small sample size and bias through selective inclusion of isolates, the 203 
findings suggest that VISA may have more severe clinical implications and impact on patient 204 
outcomes.  To date, no other published study has evaluated the outcomes of VISA infections, 205 
possibly because of  the rarity of VISA infections.  206 
 207 
Treatment Options for hVISA/VISA Infections 208 
Although reports of vancomycin failure have emerged, no data demonstrate superior outcomes 209 
with alternative antimicrobials.  Alternative antimicrobial agents with activity against 210 
hVISA/VISA include daptomycin, linezolid, ceftaroline, trimethoprim/sulfamethoxazole, 211 
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tigecycline, quinupristin/dalfopristin, and the combination of vancomycin or daptomycin with a 212 
beta-lactam.12   213 
  214 
Daptomycin 215 
Daptomycin is a potential treatment option for hVISA and VISA infections and, although it does 216 
have activity against MRSA, previous vancomycin exposure can result in some degree of cross-217 
resistance to daptomycin.48,49  Several studies have noted an in vitro association between 218 
increasing vancomycin MICs and increasing daptomycin non-susceptibility.48-50  The highest rate 219 
of daptomycin non-susceptibility was reported in a study evaluating 47 Australian hVISA and 220 
VISA isolates never exposed to daptomycin.50 The investigators noted daptomycin non-221 
susceptibly in 15% of hVISA and 38% of VISA strains.50 Because bactericidal activity with 222 
daptomycin is concentration dependent, higher doses may be necessary to treat hVISA and VISA 223 
infections with elevated daptomycin MICs, high inoculum infections (e.g., endocarditis), and 224 
infection sites characterized by poor antimicrobial penetration.51  High-dose daptomycin may 225 
prevent the selection or development of isolates with reduced susceptibility to daptomycin and 226 
subsequent treatment failure.51   227 
 228 
An in vitro study observed more rapid reduction of bacterial burden of hVISA and VISA in 229 
simulated endocardial vegetations with high-dose daptomycin (10 mg/kg/day for 8 days) and dose 230 
de-escalation (10 mg/kg/day for 4 days followed by 6 mg/kg/day for 4 days) regimens compared 231 
to that of the standard (6 mg/kg/day for 8 days) and dose escalation (6 mg/kg/day for 4 days 232 
followed by 10 mg/kg/day for 4 days) regimens.51  With respect to hVISA, the dose de-escalation 233 
regimen had a significantly increased killing effect on the hVISA strain compared to the dose 234 
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escalation regimen (P < 0.024).51  The investigators concluded that these daptomycin dosing 235 
approaches may lead to a faster cure of bacteremia in vivo and prevent the emergence of 236 
daptomycin non-susceptibility.51  However, no in vivo studies evaluating de-escalation dosing and 237 
the appropriate duration of high-dose daptomycin have been published.   The role of high-dose 238 
daptomycin alone in patients with hVISA or VISA infections is unclear.  Until more evidence is 239 
available, caution is required when considering daptomycin in patients who may be at risk for 240 
hVISA or VISA infections (e.g. high-bacterial load infections, vancomycin failure).  The 241 
determination of daptomycin susceptibility in these patients may also guide therapeutic decision 242 
making. 243 
 244 
Linezolid 245 
The role of linezolid for the treatment of invasive hVISA and VISA infections is also in question. 246 
Successful use of linezolid alone or in combination with other antimicrobial agents has been 247 
described in several case reports of vancomycin heteroresistant and intermediate MRSA 248 
endocarditis and bacteremias after vancomycin failure and in some cases after daptomycin 249 
failure.8,52-55  In one case report, a 60 year old male with an automatic implantable cardioverter-250 
defibrillator (AICD) presented with bacteremia and endocarditis initially caused by MRSA which 251 
later developed into hVISA, then daptomycin non-susceptible VISA after exposure to vancomycin 252 
and daptomycin.55  The patient initially received 6 weeks of vancomycin (trough concentrations 253 
between ≥ 15 µg/mL and ≤ 21 µg/mL), followed by approximately 25 days of daptomycin (6 254 
mg/kg every 48 hours, renal dose adjusted).  During therapy with daptomycin the defibrillator 255 
generator and leads were removed however, the patient was persistently bacteremic and febrile.  256 
Blood cultures cleared after therapy was switched to linezolid and trimethoprim/sulfamethoxazole.  257 
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The patient received at least 28 days of the combination and 6 weeks of linezolid monotherapy in 258 
total since the last positive blood culture.  One year post-treatment the patient had no infection 259 
recurrence.  After failing vancomycin and daptomycin therapy, this patient’s VISA infection was 260 
successfully treated with linezolid.  While other case reports have shown similar outcomes with 261 
the use of linezolid, in vitro studies have not shown the same efficacy.56  Evidence to recommend 262 
the use of linezolid for hVISA and VISA is insufficient.  Further study is needed to evaluate 263 
linezolid alone or in combination for hVISA and VISA infections. 264 
 265 
Ceftaroline 266 
Ceftaroline has potent in vitro bactericidal activity against MRSA including hVISA, VISA, and 267 
daptomycin non-susceptible (DNS) MRSA strains.57  The use of ceftaroline in the treatment of 268 
invasive infections (e.g., endocarditis, bacteremia, osteomyelitis) caused by hVISA, VISA, and 269 
DNS MRSA is supported by data from in vivo animal studies and human case reports.58-61  In a 270 
recent case series report, a patient with DNS VISA bacteremia and endocarditis was successfully 271 
treated with 6 weeks of ceftaroline.  The patient initially received and failed vancomycin therapy.62  272 
Blood cultures cleared within 48 hours of switching to daptomycin (6 mg/kg/day).  However, 273 
subsequent blood cultures were positive and revealed DNS VISA.  Daptomycin was discontinued, 274 
and ceftaroline (600 mg IV every 8 hours) was initiated.  While on ceftaroline, blood cultures 275 
cleared within 48 hours and remained sterile.  In vitro pharmacokinetic/pharmacodynamic studies 276 
reported enhanced ceftaroline activity against hVISA, VISA, and DNS MRSA as vancomycin and 277 
daptomycin susceptibilities decreased, which have been referred to as the “seesaw effect”.58-60  278 
While further study is needed, ceftaroline appears to be a safe and effective alternative in the 279 
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treatment of invasive hVISA, VISA, and DNS MRSA infections given its bactericidal activity, 280 
favorable safety profile, and emerging data. 281 
 282 
Combination therapy 283 
The combination of vancomycin or daptomycin and a beta-lactam antimicrobial has also been 284 
studied for treatment of hVISA and VISA infections.  Beta-lactams that have been evaluated for 285 
synergistic activity with vancomycin or daptomycin include ceftaroline, cefazolin, and 286 
piperacillin-tazobactam.63-66  In vitro and clinical case report data evaluating the combination of 287 
high-dose daptomycin (10 mg/kg/day) and trimethoprim/sulfamethoxazole also appear promising 288 
for the treatment of hVISA, VISA, and DNS MRSA infections.67,68  In vitro studies have 289 
demonstrated improved kill rates with these antimicrobial combinations.63-65  Investigators 290 
hypothesize that beta-lactam exposure may influence vancomycin-cell wall interactions to 291 
improve vancomycin activity, although further investigation is warranted.63  In summary, 292 
preliminary experimental studies show possible prospects for the treatment of hVISA and VISA 293 
infections. However, it is not yet clear which treatment options correlate with optimal clinical 294 
outcomes for patients with confirmed hVISA or VISA infections. 295 
 296 
Infection Control: Preventing the Dissemination of hVISA/VISA 297 
As with MRSA, hVISA and VISA can colonize humans and the environment despite eradication 298 
efforts.  The CDC has made several recommendations in an attempt to prevent the emergence of 299 
vancomycin non-susceptible infections.42  Infections with confirmed VISA should be reported to 300 
infection-control personnel, the patient’s primary caregiver, medical ward staff, local and state 301 
departments of health, and the CDC.  Patients and their caregivers should be educated regarding 302 
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wound care, physical hygiene, and signs of infection.69  Contact isolation in both the inpatient and 303 
outpatient setting may also limit further emergence.  Adherence to recommended infection 304 
prevention and control guidelines, appropriate antibiotic prescribing through antimicrobial 305 
stewardship programs, and active surveillance in a cohesive health care system are essential to 306 
prevent further emergence of hVISA and VISA colonization and infection.  307 
 308 
Conclusions 309 
The evolution of S. aureus to MRSA and now to hVISA and VISA is an important and ongoing 310 
public health concern.  Vancomycin is the drug of choice for invasive MRSA infections, however, 311 
its use is under question.  Over-use, suboptimal concentrations, or inappropriate use of vancomycin 312 
is speculated to be a major contributor in the emergence of hVISA and VISA.  Most alarming are 313 
the poor outcomes that have been associated with hVISA and VISA infections and the limited 314 
antimicrobials available to treat these infections.  Proper detection methods are necessary for 315 
accurate surveillance, guidance on therapeutic decision-making, and a full understanding of the 316 
implications of hVISA/VISA infections.  Until then, patients who are at risk for hVISA/VISA 317 
infections and failing vancomycin therapy may warrant further confirmatory testing for 318 
hVISA/VISA.  Based on currently available data, clinicians should, with vigilance, continue to use 319 
vancomycin per the Infectious Diseases Society of America guidelines.2,3  Alternative therapies 320 
should be considered in patients with risk factors for hVISA/VISA who are not responding 321 
clinically to vancomycin despite source control and a vancomycin MIC ≤ 2 µg/mL.  In patients 322 
infected with VISA (vancomycin MIC 4 – 8 µg/mL), an alternative antimicrobial should be 323 
considered.  Caution is advised when deciding to use daptomycin in patients with hVISA/VISA 324 
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infections because of the potential for cross-resistance.  To prevent further resistance, appropriate 325 
use of antimicrobials and implementation of infection-control guidelines are imperative. 326 
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Table 1.  CLSI susceptibility definitions for vancomycin24,25 
 2006 CLSI Update Previous CLSI Breakpoints 
 MIC MIC 
VSSA ≤ 2 g/mLa  4 g/mL 
VISA 4 – 8 g/mL 8 – 16 g/mL 
VRSA ≥ 16 g/mL  32 g/mL 
CLSI = Clinical and Laboratory Standards Institute; MIC = minimum inhibitory concentration;  
VISA = vancomycin intermediate S. aureus; VRSA = vancomycin resistant S. aureus; VSSA = vancomycin susceptible S. aureus;  
a May contain heteroresistant intermediate susceptible subpopulations with MIC > 4 g/mL.  Heteroresistant vancomycin intermediate S. aureus   
(hVISA) isolates are not identified by CLSI and can occur at vancomycin MICs as low as 0.5 µg/mL.
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Table 2. Advantages and disadvantages of laboratory detection methods for hVISA 
Confirmatory Methods 
Method Advantages Disadvantages 
PAP4,11,13,26,70  Considered the “gold 
standard”  
 High reproducibility and 
accurate detection  
 Definitive confirmation: 
Modified PAP  
 No data to show superiority to 
other techniques  
 High labor intensity 
 High-cost 
 Long turn-around time 
Screening Methods 
Method Advantages Disadvantages 
GRD E-test  
(AB Biodisk)17,19,27 
 Results ready to read following 
24 hours of incubation 
 Uses standard bacterial 
inoculum 
 Unreliable specificity and 
sensitivity 
 MET or  
High inoculum 
method11,29 
 100% reproducibility 
 Easily performed 
 Testing performed on 
nonstandard media while 
utilizing a standard McFarland 
suspension  
 Results of MET are cut-off 
points, not true MICs  
BHI screen agar 
plates7,17,28 
 Easily performed  Poor reproducibility 
 Many variations; some studies 
screened with a different agar, 
inoculum size, or used 
suspensions with higher 
bacterial concentration 
BHI = Brain Heart Infusion; GRD = Glycopeptide Resistance Detection; MET = Macromethod E-Test; MIC = minimum inhibitory concentration; 
PAP = Population Analysis Profiling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Table 3.  Predictors and outcomes of hVISA and VISA 
Predictors Outcomes 
 Previous vancomycin use 
 Prior MRSA infection or colonization 
 High bacterial load infectionsa 
 Persistent bacteremia 
 Initally low serum vancomycin levels  
(<10 μg /mL) 
 Presence of indwelling devices 
 Long duration of bacteremia, days 
 Persistent fever 
 Recurrent infections 
 Vancomycin treatment failure 
 Prolonged hospitalization 
 
hVISA = heteroresistant vancomycin intermediate S. aureus; MRSA = methicillin resistant S. aureus; VISA = vancomycin intermediate S. aureus 
a E.g.bacteremia, endocarditis, osteomyelitis, deep abscess, or prosthetic joint infection 
 
